Target intelligence / Profile preview

Vitreoretinal interface

Molecular classification
Other (anatomical interface, not a discrete molecule or protein family)
01

Overview

The vitreoretinal interface is the highly specialized zone where the vitreous gel meets the internal limiting membrane (ILM) of the retina. It is composed of the posterior vitreous cortex, the ILM, and an extracellular matrix "glue" rich in fibronectin, laminin, and various collagens, which mediate adhesion between the vitreous body and the retinal surface[1][4][7]. The strength and configuration of this interface can vary with age, topography, and pathological conditions, and abnormal traction or separation at the VRI underlies diseases such as macular hole, vitreomacular traction, and certain forms of diabetic retinopathy[4][6][7]. The VRI is a region, not a protein or gene, and direct pharmacological interventions target its extracellular matrix components rather than a canonical molecular target.

Other names
VRIvitreomacular interface
02

Mechanism of action

Enzymatic degradation of extracellular matrix proteins (fibronectin, laminin, collagen) to induce posterior vitreous detachment

03

Biological functions

Structural adhesion between the vitreous body and the retinaMaintenance of retinal architectureRegulation of tractional forces on the retina
04

Disease associations

Other (plays a role in disorders such as macular hole, vitreomacular traction, proliferative diabetic retinopathy, retinal detachment)
05

Safety considerations

Enzymatic vitreolysis can cause transient visual disturbance, retinal breaks, or detachment in rare casesSurgical intervention (vitrectomy) carries risk of retinal tears, infection, and cataract formation
06

Interacting drugs

Ocriplasmin

Beyond the preview

Go deeper on Vitreoretinal interface.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vitreoretinal interface.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call